Defendant Name:
Salix Pharmaceuticals, Ltd.
Defendant Type:
Subsidiary of Public Company
Public Company Parent:
Bausch Health Companies, Inc.
SIC Code:
2834
CUSIP:
07173410
Document Reference:
comp-pr2018-221-salix
Document Details
Legal Case Name
SEC v. Salix Pharmaceuticals, Ltd.
Document Name
Complaint
Document Date
28-Sep-2018
Document Format
Civil Proceeding
Case Number
18-cv-08886
Federal District Court
New York, Southern District of New York
Allegation Type
Issuer Reporting and Disclosure
Document Summary
The Commission stated that: "As described above, during 2013 and 2014, Salix, directly or indirectly, used the means or instrumentalities of interstate commerce, or of the mails, or of the facilities of a national securities exchange, in connection with the purchase or sale of Salix securities, to knowingly or recklessly make untrue statements of material facts or omit to state material facts that were necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading in: a. Salix earnings calls in 2013 and 2014, and b. the Risk Factors and MD&A sections of Salix's quarterly Reports on Form 10-Q for the first and second quarters of 2014."
